|
1
|
Brown RL, de Souza JA and Cohen EE:
Thyroid cancer: Burden of illness and management of disease. J
Cancer. 2:193–199. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Nikiforova MN and Nikiforov YE: Molecular
genetics of thyroid cancer: Implications for diagnosis, treatment
and prognosis. Expert Rev Mol Diagn. 8:83–95. 2008. View Article : Google Scholar
|
|
3
|
Lang BH, Wong KP, Wan KY and Lo CY:
Significance of metastatic lymph node ratio on stimulated
thyroglobulin levels in papillary thyroid carcinoma after
prophylactic unilateral central neck dissection. Ann Surg Oncol.
19:1257–1263. 2012. View Article : Google Scholar :
|
|
4
|
Fabian MR, Sonenberg N and Filipowicz W:
Regulation of mRNA translation and stability by microRNAs. Annu Rev
Biochem. 79:351–379. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Guo H, Ingolia NT, Weissman JS and Bartel
DP: Mammalian microRNAs predominantly act to decrease target mRNA
levels. Nature. 466:835–840. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
McManus MT: MicroRNAs and cancer. Semin
Cancer Biol. 13:253–258. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Farazi TA, Spitzer JI, Morozov P and
Tuschl T: miRNAs in human cancer. J Pathol. 223:102–115. 2011.
View Article : Google Scholar :
|
|
9
|
Ebrahimi F, Gopalan V, Smith RA and Lam
AK: miR-126 in human cancers: Clinical roles and current
perspectives. Exp Mol Pathol. 96:98–107. 2014. View Article : Google Scholar
|
|
10
|
Zhao C, Li Y, Zhang M, Yang Y and Chang L:
miR-126 inhibits cell proliferation and induces cell apoptosis of
hepatocellular carcinoma cells partially by targeting Sox2. Hum
Cell. 28:91–99. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Jiang L, Tao C, He A and He X:
Overexpression of miR-126 sensitizes osteosarcoma cells to
apoptosis induced by epigallocatechin-3-gallate. World J Surg
Oncol. 12:3832014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kim MK, Jung SB, Kim JS, Roh MS, Lee JH,
Lee EH and Lee HW: Expression of microRNA miR-126 and miR-200c is
associated with prognosis in patients with non-small cell lung
cancer. Virchows Arch. 465:463–471. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chen H, Li L, Wang S, Lei Y, Ge Q, Lv N,
Zhou X and Chen C: Reduced miR-126 expression facilitates
angiogenesis of gastric cancer through its regulation on VEGF-A.
Oncotarget. 5:11873–11885. 2014.PubMed/NCBI
|
|
14
|
Wang X, Tang S, Le SY, Lu R, Rader JS,
Meyers C and Zheng ZM: Aberrant expression of oncogenic and
tumor-suppressive microRNAs in cervical cancer is required for
cancer cell growth. PLoS One. 3:e25572008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yamaguchi T, Iijima T, Wakaume R,
Takahashi K, Matsumoto H, Nakano D, Nakayama Y, Mori T, Horiguchi S
and Miyaki M: Underexpression of miR-126 and miR-20b in hereditary
and nonhereditary colorectal tumors. Oncology. 87:58–66. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Li Z, Li N, Wu M, Li X, Luo Z and Wang X:
Expression of miR-126 suppresses migration and invasion of colon
cancer cells by targeting CXCR4. Mol Cell Biochem. 381:233–242.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kitano M, Rahbari R, Patterson EE, Xiong
Y, Prasad NB, Wang Y, Zeiger MA and Kebebew E: Expression profiling
of difficult-to-diagnose thyroid histologic subtypes shows distinct
expression profiles and identify candidate diagnostic microRNAs.
Ann Surg Oncol. 18:3443–3452. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hagan JP and Croce CM: MicroRNAs in
carcinogenesis. Cytogenet Genome Res. 118:252–259. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Osada H and Takahashi T: MicroRNAs in
biological processes and carcinogenesis. Carcinogenesis. 28:2–12.
2007. View Article : Google Scholar
|
|
20
|
Farazi TA, Hoell JI, Morozov P and Tuschl
T: MicroRNAs in human cancer. Adv Exp Med Biol. 774:1–20. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Leonardi GC, Candido S, Carbone M,
Colaianni V, Garozzo SF, Cinà D and Libra M: microRNAs and thyroid
cancer: Biological and clinical significance (Review). Int J Mol
Med. 30:991–999. 2012.PubMed/NCBI
|
|
22
|
Wei WJ, Shen CT, Song HJ, Qiu ZL and Luo
QY: MicroRNAs as a potential tool in the differential diagnosis of
thyroid cancer: A systematic review and meta-analysis. Clin
Endocrino. Dec 16–2014.Epub ahead of print. View Article : Google Scholar
|
|
23
|
Huang C, Cai Z, Huang M, Mao C, Zhang Q,
Lin Y, Zhang X, Tang B, Chen Y, Wang X, et al: miR-219-5p modulates
cell growth of papillary thyroid carcinoma by targeting estrogen
receptor α. J Clin Endocrinol Metab. 100:E204–E213. 2015.
View Article : Google Scholar
|
|
24
|
Zhu H, Fang J, Zhang J, Zhao Z, Liu L,
Wang J, Xi Q and Gu M: miR-182 targets CHL1 and controls tumor
growth and invasion in papillary thyroid carcinoma. Biochem Biophys
Res Commun. 450:857–862. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Li D, Jian W, Wei C, Song H, Gu Y, Luo Y
and Fang L: Downregulation of miR-181b promotes apoptosis by
targeting CYLD in thyroid papillary cancer. Int J Clin Exp Pathol.
7:7672–7680. 2014.
|
|
26
|
Chou CK, Yang KD, Chou FF, Huang CC, Lan
YW, Lee YF, Kang HY and Liu RT: Prognostic implications of miR-146b
expression and its functional role in papillary thyroid carcinoma.
J Clin Endocrinol Metab. 98:E196–E205. 2013. View Article : Google Scholar
|
|
27
|
Fish JE, Santoro MM, Morton SU, Yu S, Yeh
RF, Wythe JD, Ivey KN, Bruneau BG, Stainier DY and Srivastava D:
miR-126 regulates angiogenic signaling and vascular integrity. Dev
Cell. 15:272–284. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kuhnert F, Mancuso MR, Hampton J,
Stankunas K, Asano T, Chen CZ and Kuo CJ: Attribution of vascular
phenotypes of the murine Egfl7 locus to the microRNA miR-126.
Development. 135:3989–3993. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Liu LY, Wang W, Zhao LY, Guo B, Yang J,
Zhao XG, Hou N, Ni L, Wang AY, Song TS, et al: mir-126 inhibits
growth of SGC-7901 cells by synergistically targeting the oncogenes
PI3KR2 and Crk, and the tumor suppressor PLK2. Int J Oncol.
45:1257–1265. 2014.PubMed/NCBI
|
|
30
|
Feng X, Wang H, Ye S, Guan J, Tan W, Cheng
S, Wei G, Wu W, Wu F and Zhou Y: Up-regulation of microRNA-126 may
contribute to pathogenesis of ulcerative colitis via regulating
NF-kappaB inhibitor IκBα. PLoS One. 7:e527822012. View Article : Google Scholar
|
|
31
|
Li H, Meng F, Ma J, Yu Y, Hua X, Qin J and
Li Y: Insulin receptor substrate-1 and Golgi phosphoprotein 3 are
downstream targets of miR-126 in esophageal squamous cell
carcinoma. Oncol Rep. 32:1225–1233. 2014.PubMed/NCBI
|
|
32
|
Jia AY, Castillo-Martin M, Bonal DM,
Sánchez-Carbayo M, Silva JM and Cordon-Cardo C: MicroRNA-126
inhibits invasion in bladder cancer via regulation of ADAM9. Br J
Cancer. 110:2945–2954. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Du C, Lv Z, Cao L, Ding C, Gyabaah OA, Xie
H, Zhou L, Wu J and Zheng S: MiR-126-3p suppresses tumor metastasis
and angiogenesis of hepatocellular carcinoma by targeting LRP6 and
PIK3R2. J Transl Med. 12:2592014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Joiner DM, Ke J, Zhong Z, Xu HE and
Williams BO: LRP5 and LRP6 in development and disease. Trends
Endocrinol Metab. 24:31–39. 2013. View Article : Google Scholar :
|
|
35
|
Peröbner I, Karow M, Jochum M and Neth P:
LRP6 mediates Wnt/β-catenin signaling and regulates adipogenic
differentiation in human mesenchymal stem cells. Int J Biochem Cell
Biol. 44:1970–1982. 2012. View Article : Google Scholar
|
|
36
|
Brown SD, Twells RC, Hey PJ, Cox RD, Levy
ER, Soderman AR, Metzker ML, Caskey CT, Todd JA and Hess JF:
Isolation and characterization of LRP6, a novel member of the low
density lipoprotein receptor gene family. Biochem Biophys Res
Commun. 248:879–888. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Li Y, Lu W, He X, Schwartz AL and Bu G:
LRP6 expression promotes cancer cell proliferation and
tumorigenesis by altering beta-catenin subcellular distribution.
Oncogene. 23:9129–9135. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zhang Y, Zheng D, Xiong Y, Xue C, Chen G,
Yan B and Ye Q: miR-202 suppresses cell proliferation in human
hepatocellular carcinoma by downregulating LRP6
post-transcriptionally. FEBS Lett. 588:1913–1920. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Wang J, Wang X, Li Z, Liu H and Teng Y:
MicroRNA-183 suppresses retinoblastoma cell growth, invasion and
migration by targeting LRP6. FEBS J. 281:1355–1365. 2014.
View Article : Google Scholar
|
|
40
|
Zeng XC, Liu FQ, Yan R, Yi HM, Zhang T,
Wang GY, Li Y and Jiang N: Downregulation of miR-610 promotes
proliferation and tumorigenicity and activates Wnt/β-catenin
signaling in human hepatocellular carcinoma. Mol Cancer.
13:2612014. View Article : Google Scholar
|
|
41
|
Wang J, Guan X, Guo F, Zhou J, Chang A,
Sun B, Cai Y, Ma Z, Dai C, Li X, et al: miR-30e reciprocally
regulates the differentiation of adipocytes and osteoblasts by
directly targeting low-density lipoprotein receptor-related protein
6. Cell Death Dis. 4:e8452013. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Zhang W, Shen C, Li C, Yang G, Liu H, Chen
X, Zhu D, Zou H, Zhen Y, Zhang D, et al: miR-577 inhibits
glioblastoma tumor growth via the Wnt signaling pathway. Mol
Carcinog. Mar 12–2015.Epub ahead of print. View Article : Google Scholar
|
